This review aims to highlight the clinical implications of various structurally distinct SGLT2 inhibitors, considering their cardioprotective, nephroprotective, and metabolic effects, as well as their potential relevance in oncology, providing a coherent perspective on their possible applications in cancer patients. The gene discussed is SLC5A2; the disease is cancer.